Cellsource
57 West 57th Street, Suite 400, New York, 10019, United States
Overview
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Biotechnology
- Developer Platform
- Medical
Investment portfolio
- Tailor App
Led · Equity · Aug 2024
Tailor App operates a live commerce consulting service (LIVURU) and a proprietary SNS SaaS (snsforce) that automates Instagram DMs and analyzes live comments and engagement. LIVURU offers end-to-end live commerce production and claims domestic No.1 live commerce performance per a 2022 Japan Marketing Research Institute survey, backed by over 800 live broadcasts. snsforce captures comment trends and action data to visualize viewer reactions and automatically send DMs to build purchase funnels. The company says it combines brand experience and technology to spread product stories and drive consumer behavior. Tailor App plans product development in partnership with CellSource focused on regenerative-medicine-related offerings and aims to leverage investor resources to pursue overseas expansion. Founded in July 2020 and headquartered in Shibuya, Tokyo, the company has moved from self-funded operations into this external financing round.